An Open-label, Randomised, Single-dose, Two-way Crossover Study in Healthy Male and Female Volunteers to Evaluate the Relative Bioavailability of a New Oral Formulation of Meloxicam, Movalis Capsules 15 mg, Versus Movalis Tablets 15 mg, After Administration Under Fasting State
Phase of Trial: Phase I
Latest Information Update: 22 Nov 2018
At a glance
- Drugs Meloxicam (Primary)
- Indications Ankylosing spondylitis; Back pain; Gout; Juvenile rheumatoid arthritis; Neuropathic pain; Osteoarthritis; Periarthritis; Rheumatoid arthritis
- Focus Pharmacokinetics
- Sponsors Boehringer Ingelheim
- 12 Nov 2018 Status changed from recruiting to completed.
- 09 Oct 2018 Status changed from not yet recruiting to recruiting.
- 01 Oct 2018 New trial record